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Minority K65R 
Variants and Early 
Failure of 
Antiretroviral 
Therapy in 
HIV-1–infected 
Eritrean Immigrant
To the Editor: Genotypic 
drug resistance testing before 
initiation of fi rst-line antiretroviral 
therapy (ART) is recommended to 
detect drug-resistant viruses and to 
avoid treatment failure caused by 
preexisting drug-resistant viruses 
(1). However, standard resistance 
testing cannot detect drug-resistant 
HIV-1 minority variants unless they 
represent 20%–25% of the population 
(2). Approximately 15% of those 
who underwent seroconversion in the 
acute phase in industrialized settings 
harbor drug-resistant HIV-1 minority 
variants, while standard resistance 
testing did not detect drug-resistant 
viruses in those patients (3). We report 
the case of a treatment-naive HIV-1–
infected patient with early treatment 
failure because of preexisting minority 
K65R-harboring HIV-1 variants. 
A 32-year-old immigrant to 
Switzerland from Eritrea with a 
recently diagnosed HIV-1 subtype 
C infection was seen at University 
Hospital, Zurich. On the basis of the 
low CD4+ T-cell count of 69 cells/μL 
(15%) and high HIV-1 viral load of 
980,000 copies/mL plasma, we started 
directly observed ART with tenofovir 
and emtricitabine plus nevirapine. 
Genotypic resistance testing showed 
no evidence of resistance. Within the 
fi rst 4 weeks of ART, the viral load 
decreased to 540; however, 4 weeks 
later it increased to 15,000, and then 
12 days later to 71,000 HIV-1 RNA 
copies/mL (Figure). Resistance testing 
at this time revealed the reverse 
transcriptase (RT) mutations K65R, 
K103N, and M184V, which confer 
resistance to all prescribed drugs. 
ART was changed to lamivudine/
zidovudine, darunavir/ritonavir, and 
etravirine, and subsequently viremia 
decreased and remained undetectable.
We hypothesized that preexisting 
drug-resistant HIV-1 minority variants 
might have caused this early treatment 
failure. Thus, we performed clonal 
analysis of the RT gene before and 
during ART. At baseline, 17/222 
clones (7.7%) carried the K65R 
mutation, synonymous to ≈51,000 
HIV-1 RNA copies. Later, the K65R 
mutation was comprised in all clones. 
Further preexisting drug-resistance 
mutations have been detected in 
single, K65 wild-type, separate clones: 
K70R, V106A, and V108I. However, 
neither the K103N nor the M184V 
mutation was detected in any of those 
222 clones, but both mutations were 
rapidly selected during early treatment 
failure.
Thus, the presence of the K65R 
mutation in a substantial fraction 
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of the virus population and the 
rapid acquisition of the K103N and 
M184V mutations led eventually to 
early treatment failure. We cannot 
formally rule out that K103N 
mutants were present before ART at 
a very low frequency <0.5% and that 
K65R/K103N double mutants were 
potentially selected. The M184V 
mutation was acquired later because 
only 12.5% of K65R/K103N viruses 
carried the M184V mutation at the fi rst 
time point during treatment failure.
Because of the considerable 
absolute number of less replication-
competent K65R-harboring viruses in 
the patient, we assume that this variant 
has been transmitted. The additional 
presence of isolated, nonnucleoside 
RT inhibitor (NNRTI)/nucl eoside 
RT inhibitor (NRTI) resistance 
mutations is another indication for 
the transmission of drug-resistant 
viruses, although they and the K65R 
mutation were not found in the same 
viral genomes. Presumably, the index 
patient was treated with nevirapine, 
stavudine, and lamivudine, the 
commonly prescribed fi rst-line ART 
in resource-limited settings (4).
The prevalence of K65R-
harboring drug-resistant HIV-1 
minority variants is not negligible in 
treatment-naive patients. We have 
shown that 2.7% of HIV-1–infected 
patients, mainly those infected 
with HIV-1 subtype B, harbor 
the K65R mutation as a minority 
variant (5), which is comparable 
with the prevalence of minority 
K65R-harboring variants (4%) in 
patients from South Africa who 
are infected with HIV-1 subtype C 
(6). A meta-analysis showed that 
limited or unavailable HIV-1 RNA 
monitoring in combination with ART 
regimens with a low genetic barrier 
to resistance in resource-limited 
settings is associated with high rates 
of NNRTI/NRTI resistance in patients 
for whom ART fails (7). Although 
ritonavir-boosted protease inhibitors 
containing ART regimens have a 
higher genetic barrier to resistance 
and would be preferable in such 
settings, they are generally not part of 
fi rst-line therapy in resource-limited 
settings. Thus, proper monitoring 
and drug-resistance testing would be 
desirable when using NNRTI-based 
ART regimens. Moreover, it could be 
benefi cial to apply sensitive assays for 
the detection of drug-resistant HIV-1 
minority variants in clinical practice. 
However, clinical cut-off levels for 
those minority variants need to be 
defi ned.
Immigration from resource-
limited settings is increasing, and 
data suggest that minority variants 
harboring the K65R mutation are 
quite prevalent in those infected with 
HIV-1 subtype C, who are treatment 
naive (6). The case described here 
demonstrates that these drug-resistant 
HIV-1 minority variants can quickly 
accumulate further drug-resistance 
mutations and lead to early treatment 
failure, especially in the context of 
an ART regimen with low genetic 
barriers to resistance. This case was 
the fi rst among immigrants treated 
in our center, but, given the potential 
for considerable transmission rates 
of resistance in countries that lack 
virologic monitoring, this mutation 
could become a larger problem.
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Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations in a treatment-
naive person from Eritrea, infected with HIV-1 subtype C, who was experiencing early 
antiretroviral therapy (ART) failure. Viral load (circles) was measured by using the Cobas 
AmpliPrep TaqMan HIV-1 test version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland) with 
a detection limit of 20 HIV-1 RNA copies/mL plasma (dotted line). CD4+ T-cell count is 
depicted in crosses. Genotypic resistance testing (GRT) based on population sequencing 
was performed at time points indicated by black arrows. Duration of different ART regimens 
is shown in shades of gray. Part of the HIV-1 reverse transcriptase (codons 52–218) gene 
was cloned and sequenced at time points before ART and during virologic failure: n = 222 
clones at –2 days before ART, n = 24 clones, and n = 38 clones during virologic failure, 
respectively. The dynamics of the selection of the K65R, K103N, and M184V mutations are 
depicted by percentages and 95% confi dence intervals. TDF, tenofovir; FTC, emtricitabine; 
NVP, nevirapine; AZT, zidovudine; 3TC, lamivudine; DRV/r, darunavir in combination with 
ritonavir; ETV, etravirine. 
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Diagnosis of 
Rickettsioses from 
Eschar Swab 
Samples, Algeria
To the Editor: Tick-borne 
rickettsioses are zoonoses caused by 
intracellular bacteria belonging to 
the spotted fever group rickettsiae 
(1). The main clinical signs are high 
fever, maculopapular rash, and an 
inoculation eschar at the site of the 
tick bite (corresponding to the portal 
of entry of rickettsiae into the host). 
Recently, several rickettsioses were 
diagnosed by using swab samples 
from skin lesions (2,3). In an animal 
model, as long as eschars were present, 
rickettsial DNA was detected (2). Our 
aim was to evaluate the advantage of 
skin swab samples for diagnosis of 
rickettsial diseases in a country where 
rickettsioses are endemic (4).
From July 2009 through October 
2010, a total of 39 patients in the 
infectious disease department of Oran 
Teaching Hospital, Algeria (27 men, 
12 women; median age 46.5 years) 
were included in a prospective study. 
The mean (± SD) interval between 
onset of lesions and consultation 
was 7 ± 1.8 days. Underlying 
conditions were present in 13 (33%) 
patients: diabetes (4 patients, 10.2%), 
hypertension (2 patients, 5%), chronic 
renal failure (1 patient, 2.5%), cervical 
cancer (1 patient, 2.5%), bronchial 
cancer (1 patient, 2.5%), and tobacco 
consumption (6 patients, 15%). Fever 
and generalized maculopapular rash 
(also on palms and soles) were found 
for 38 (97.4%) patients, including 
5 (12.8%) with purpuric rash. One 
(2.5%) patient had 2 eschars on 
the back. Eschars were frontal (1 
[2.5%] patient), cervical (3  [7%]), 
axillary (4 [10.2%]), on the back (6 
[15%]), on the abdomen (2 [5%)], 
on the thorax (1 [2.5%]), inguinal (6 
[15%]), on the leg (8 [20.5%]), on 
the arm (1 [2.5%]), on the buttock (2 
[5%]), on the breast (1 [2.5%]), on 
the nipple (1 [2.5%]), on the penis 
(1 [2.5%]), and on the scrotum (2 
[5%]). Conjunctivitis was reported for 
24 (61.5%) patients and myalgia for 
34 (87.8%). Lymphadenopathy was 
found near the eschar for 8 (20.5%) 
patients. Antimicrobial drug therapy 
(doxycycline 200 mg 1×/d) for 3.5 ± 
1.4 days was empirically prescribed 
for all case-patients before diagnoses 
were confi rmed.
A dry sterile swab (Copan, 
Brescia, Italy) sample was collected 
from the inoculation eschar of each 
patient by the same person (N.M.). 
Two patients had 2 swab samples 
collected from the same eschar. Only 
1 swab sample was collected from 
the patient with 2 eschars. Scabs 
were removed from eschars before 
swabbing. The swabs, while being 
rotated vigorously, were directed to 
the base of the eschar at a 50°–60° 
angle for 5–6 times. For 4 patients, an 
eschar biopsy sample was collected 
under sterile conditions. Swabs were 
then placed back in their tubes and 
stored at –20°C before transportation 
to Unité des Rickettsies, Marseille, 
France.
In the laboratory, each sample 
was placed in 2 mL of culture 
medium. DNA was extracted from 
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